- English (USA)
- English (UK)
- English (India)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Teva Pharma Industries Ltd ADR (TEVA)
Teva Pharma Industries Ltd ADR stock price live, this page displays NYSE TEVA stock exchange data. View the TEVA premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Teva Pharma Industries Ltd ADR real time stock price chart below.
What Is the Teva Pharma Industries Ltd ADR Stock Price Today?
The Teva Pharma Industries Ltd ADR stock price today is 44.50.
What Is the Stock Symbol for Teva Pharma Industries Ltd ADR?
The stock symbol for Teva Pharma Industries Ltd ADR is "TEVA."
What Stock Exchange Does Teva Pharma Industries Ltd ADR Trade On?
Teva Pharma Industries Ltd ADR is listed and trades on the NYSE stock exchange.
Is Teva Pharma Industries Ltd ADR a Good Stock to Buy?
Determining whether Teva Pharma Industries Ltd ADR—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the TEVA quote. (ISIN: IL0006290147)
What Is the Teva Pharma Industries Ltd ADR Stock Price Today?
The Teva Pharma Industries Ltd ADR stock price today is 44.50.
What Is the Stock Symbol for Teva Pharma Industries Ltd ADR?
The stock symbol for Teva Pharma Industries Ltd ADR is "TEVA."
What Stock Exchange Does Teva Pharma Industries Ltd ADR Trade On?
Teva Pharma Industries Ltd ADR is listed and trades on the NYSE stock exchange.
Is Teva Pharma Industries Ltd ADR a Good Stock to Buy?
Determining whether Teva Pharma Industries Ltd ADR—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the TEVA quote. (ISIN: IL0006290147)
Currency in USD
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
43.43
44.57
52 wk Range
24.01
44.57
Trading near 52-week High
1/2
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
43.4344.57
52 wk Range
24.0144.57
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
TEVA Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Price Target
50.29
Upside
+13.02%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
RSI suggests the stock is in overbought territory
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy
Analyst Ratings
13 Buy
2 Hold
0 Sell
Ratings:
15 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 50.29
(+13.02% Upside)
Teva Pharma Industries Ltd ADR SWOT Analysis
Pivot to Growth | Teva's strategic shift from generics to innovative medicines yields positive results, with ten consecutive quarters of growth amid industry challenges |
Financial Outlook | Teva projects 2025 revenue between $16.8-17.2 billion, with analysts forecasting EPS growth from $2.50 to $3.00 by 2027, despite near-term headwinds |
Pipeline Potential | Duvakitug emerges as a game-changer in IBD treatment, showcasing best-in-class efficacy and positioning Teva for significant market share in specialty medicines |
Margin Expansion | Ambitious $700 million cost-cutting program aims to boost operating margins to 30% by 2027, with 20% of targeted savings already achieved |
Teva Pharma Industries Ltd ADR Earnings Call Summary for Q3/2026
- Teva Q3 2026 EPS of $0.86 beat estimates by 19.4%; revenue of $4.4B topped forecasts by 3.5%; shares rose 4.08% to near 52-week high of $42.77.
- Gross margin expanded 345 bps to 58.7% YoY, reflecting shift to higher-margin branded drugs; company repaid $1.8B debt in October, strengthening balance sheet.
- Teva raised FY 2026 guidance: revenue $16.7-17B, EPS $1.92-2.11, free cash flow $2.1-2.4B; AUSTEDO hit $2.5B target one year early, now targeting $3B+ peak.
- Innovative portfolio revenue surged 32% YoY while generics fell 16% on lower REVLIMID sales; WELTRUZA launch expected Q4 2026 with revenue in H2 2027.
- CEO Francis emphasized transformation to 'high-growth biopharma'; key risks include IRA pricing impact on AUSTEDO, biosimilar litigation, and competitive pressures.
Last Updated: 2026-11-03, 09:52 a/m
Read Full TranscriptEarnings
Latest Release
Nov 03, 2026
EPS / Forecast
0.86 / 0.72
Revenue / Forecast
4.4B / 4.25B
Compare TEVA to Peers and Sector
Metrics to compare | TEVA | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipTEVAPeersSector | |
|---|---|---|---|---|
P/E Ratio | 102.6x | 42.0x | −0.2x | |
PEG Ratio | −3.33 | −1.76 | 0.00 | |
Price/Book | 6.5x | 5.7x | 2.6x | |
Price / LTM Sales | 3.0x | 5.1x | 2.8x | |
Upside (Analyst Target) | 13.0% | 9.9% | 61.2% | |
Fair Value Upside | Unlock | 2.0% | 9.7% | Unlock |
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company also focuses on the central nervous system (CNS), respiratory, oncology, and other areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin’s lymphoma; COPAXONE, glatiramer acetate injection to treat patients with relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of tardive dyskinesia, chorea associated with Huntington’s disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; QVAR RediHaler to treat asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax budesonide and formoterol powder inhaler; AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder; and ProAir RespiClick inhalation powder. It offers its OTC products under the SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. The company has collaboration agreements with MedinCell S.A.; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. Teva Pharmaceutical Industries Limited was founded in 1901 and is based in Tel Aviv-Yafo, Israel.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Teva ADR (TEVA) Stock Price Today?
The Teva ADR stock price today is 44.50 USD.
What Stock Exchange Does Teva ADR Trade On?
Teva ADR is listed and trades on the New York Stock Exchange.
What Is the Stock Symbol for Teva ADR?
The stock symbol for Teva ADR is "TEVA."
What Is the Teva ADR Market Cap?
As of today, Teva ADR market cap is 51.92B USD.
What Is Teva ADR's Earnings Per Share (TTM)?
The Teva ADR EPS (TTM) is 0.44.
When Is the Next Teva ADR Earnings Date?
Teva ADR will release its next earnings report on Feb 10, 2027.
From a Technical Analysis Perspective, Is TEVA a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has Teva ADR Stock Split?
Teva ADR has split 4 times.
How Many Employees Does Teva ADR Have?
Teva ADR has 32008 employees.
What is the current trading status of Teva ADR (TEVA)?
As of Nov 15, 2026, Teva ADR (TEVA) is trading at a price of 44.50 USD, with a previous close of 44.50 USD. The stock has fluctuated within a day range of 43.43 USD to 44.57 USD, while its 52-week range spans from 24.01 USD to 44.56 USD.
What Is Teva ADR (TEVA) Price Target According to Analysts?
The average 12-month price target for Teva ADR is 50.29 USD, with a high estimate of 57 USD and a low estimate of 42.12 USD. 13 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +13.02% Upside potential.
What Is the TEVA Premarket Price?
TEVA's last pre-market stock price is 43.90 USD. The pre-market share volume is 214,930.00, and the stock has decreased by 0.25, or 0.57%.
What Is the TEVA After Hours Price?
TEVA's last after hours stock price is 44.30 USD, the stock has decreased by -0.20, or -0.45%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.